Differences
This shows you the differences between two versions of the page.
Both sides previous revision Previous revision | |||
pi3k_akt_mtor_pathway [2020/04/24 23:56] administrador |
pi3k_akt_mtor_pathway [2021/01/21 16:31] (current) administrador |
||
---|---|---|---|
Line 1: | Line 1: | ||
+ | ====== PI3K/ | ||
+ | The [[PI3K]]/ | ||
+ | |||
+ | Dysregulation of the PI3K/ | ||
+ | ---- | ||
+ | While cancer metabolism in other organs is commonly associated with upregulated glycolysis (i.e. Warburg effect) and hyperactivation of PIK3/ | ||
+ | ((Duggan MR, Weaver M, Khalili K. PAM (PIK3/ | ||
+ | ---- | ||
+ | PI3K activation phosphorylates and activates AKT, localizing it in the [[plasma]] membrane. | ||
+ | |||
+ | AKT can have a number of downstream effects such as activating CREB, inhibiting [[p27]], localizing FOXO in the cytoplasm, activating PtdIns-3ps, and activating mTOR which can affect transcription of p70 or 4EBP1. | ||
+ | |||
+ | There are many known factors that enhance the PI3K/AKT pathway including EGF, shh, IGF-1, insulin, and CaM. | ||
+ | |||
+ | The pathway is antagonized by various factors including [[PTEN]], [[GSK3B]], and HB9. In many cancers, this pathway is overactive, thus reducing apoptosis and allowing proliferation. This pathway is necessary, however, to promote growth and proliferation over differentiation of adult stem cells, neural stem cells specifically | ||
+ | |||
+ | It is the difficulty in finding an appropriate amount of proliferation versus differentiation that researchers are trying to determine in order to utilize this balance in the development of various therapies. Additionally, | ||
+ | |||
+ | The [[Phosphoinositide 3 kinase]] (PI3K)/Akt pathway is known to play a major role in [[angiogenesis]]. Studies have shown that the phosphatase and tensin homologue deleted on chromosome ten ([[PTEN]]), a tumor suppressor, is an antagonist regulator of the PI3K/Akt pathway and mediates angiogenesis by activating [[vascular endothelial growth factor]] (VEGF) expression. | ||
+ | |||
+ | {{ :: | ||
+ | |||
+ | PI3Ks are a family of related intracellular signal transducer enzymes capable of phosphorylating the 3 position hydroxyl group of the inositol ring of phosphatidylinositol (PtdIns). | ||
+ | |||
+ | The pathway, with oncogene PIK3CA and tumor suppressor PTEN, is implicated in insensitivity of cancer tumors to insulin and IGF1, in calorie restriction. | ||
+ | ---- | ||
+ | Current standard treatment for [[glioma]] patients is surgical removal followed by radiotherapy and adjuvant chemotherapy. Due to therapeutic resistance and tumor recurrence, efforts are ongoing to identify the molecules that are fundamental to regulate the tumor progression and provide additional methods for individual treatment of glioma patients. By studying the initiation and maintenance of glioma, studies focused on the targets of [[tyrosine kinase receptor]]s including [[EGFR]], [[PDGFR]] and other crucial signal pathways such as [[PI3K]]/ | ||
+ | ((Lin L, Cai J, Jiang C. Recent advances in targeted therapy for glioma. Curr | ||
+ | Med Chem. 2016 Dec 23. [Epub ahead of print] PubMed PMID: 28019637. | ||
+ | )). | ||
+ | ---- | ||
+ | PI3K/ | ||
+ | ((Bujko M, Kober P, Tysarowski A, Matyja E, Mandat T, Bonicki W, Siedlecki JA. | ||
+ | EGFR, PIK3CA, KRAS and BRAF mutations in meningiomas. Oncol Lett. 2014 | ||
+ | Jun; | ||
+ | PMC4049666. | ||
+ | )). | ||
+ | |||
+ | ===== mTOR pathway activation in focal cortical dysplasia ===== | ||
+ | |||
+ | [[mTOR pathway activation in focal cortical dysplasia]] | ||